SYSTEMIC SCLEROSIS

This early-stage study is testing a new treatment called RD06-04, which uses a patient's own immune cells modified to target and attack faulty B cells. The goal is to see if it is safe and tolerable for people with active autoimmune diseases like lupus, scleroderma, and Sjögren's…

This study tests a new treatment using donor immune cells (CAR T-cells) that are engineered to target and destroy faulty immune cells in people with severe lupus or scleroderma. The goal is to control the disease by resetting the immune system. The trial involves 18 adults whose …

This early-phase study tests a new treatment called KITE-363 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathy that haven't improved with standard therapies. KITE-363 uses a patient's own immune cells, modified to target and attack faul…

This early-phase study tests a new treatment that uses a patient's own immune cells, modified to target and calm the overactive immune system causing severe lupus or scleroderma. About 48 adults with these hard-to-treat autoimmune diseases will receive the therapy to see if it is…

This study tests whether anifrolumab, an injected drug, can help people with systemic sclerosis (scleroderma) — a disease that causes skin thickening and can damage organs like the lungs. About 314 adults aged 18 to 70 with early-stage disease will receive either the drug or a pl…

This study tests whether baricitinib, a drug that calms the immune system, can help people with systemic sclerosis—a rare disease that causes skin to harden and can affect organs like the lungs and heart. About 60 adults with early-stage disease will receive either baricitinib or…

This early-stage trial tests a treatment called KYV-101, which uses a patient's own modified immune cells to target and destroy certain B-cells thought to drive systemic sclerosis. The study involves 3 adults with active diffuse cutaneous systemic sclerosis. The main goals are to…

This study tests a new medicine called MT-0551 to see if it can reduce skin thickening in people with systemic sclerosis, a rare disease that causes the skin to harden and tighten. About 80 adults with moderate skin thickening will receive either the drug or a placebo for 26 week…

This study looks at how safe and effective the Shingrix vaccine is for people with autoimmune rheumatic diseases like rheumatoid arthritis and lupus, who are at higher risk for shingles. About 2,000 participants will receive the vaccine or a placebo to check for disease flares an…

This study tests whether a fecal transplant (FMT) can safely improve chronic diarrhea in people with systemic sclerosis, an autoimmune disease. Twenty adults will receive either FMT or a placebo, and researchers will track side effects and symptom changes. The goal is to see if t…

This study looks at CT scans from 1,000 people with systemic sclerosis to see if certain features in the lungs can predict worsening lung disease, development of pulmonary hypertension, and survival. Researchers will use deep learning to analyze the scans. The goal is to find bet…

This study looks at whether giving people with inflammatory arthritis extra support—like a list of local resources, help from a community specialist, or a nurse navigator—can reduce missed doctor visits. About 100 adults with conditions like rheumatoid arthritis or lupus who have…